TRACON Story

<div class='circular--portrait' style='background:#754DEB;color: #F0FFF0;font-size:4em;'>TP</div>
TCON -- USA Stock  

USD 4.94  0.42  9.29%

Today's article will outline TRACON Pharmaceuticals. We will evaluate if TRACON Pharmaceuticals shares are reasonably priced going into October. TRACON Pharmaceuticals is at this time traded for 6.30. The entity has historical hype elasticity of 0.12. The average price elasticity to hype of competition is about 1.8. The firm is anticipated to increase in value after the next headline, with the price going to jump to 5.39. The latest volatility of media hype impact on the company stock price is is way over 100 percent making price predictions on social media along less reliable. The price upswing on the next news is estimated to be 2.28%, whereas the daily expected return is at this time at 2.06%. The volatility of related hype on TRACON Pharmaceuticals is about 877.29% with expected price after next announcement by competition of 8.1 Given the investment horizon of 30 days, the next anticipated press release will be in about 7 days.
Published over a month ago
View all stories for TRACON Pharmaceuticals | View All Stories
Should I exit my TRACON Pharmaceuticals (NASDAQ:TCON) holdings?
This firm's average rating is Buy from 3 analysts. We provide trade recommendation to complement the latest expert consensus on TRACON Pharmaceuticals. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available now.
The successful prediction of TRACON Pharmaceuticals stock price could yield a significant profit to investors. But is it possible? The efficient-market hypothesis suggests that all published stock prices of traded companies, such as TRACON Pharmaceuticals, already reflect all publicly available information. This academic statement is a fundamental principle of many financial and investing theories used today. However, the typical investor usually disagrees with a 'textbook' version of this hypothesis and continually tries to find mispriced stocks to increase returns. We use internally-developed statistical techniques to arrive at the intrinsic value of TRACON Pharmaceuticals based on TRACON Pharmaceuticals hews, social hype, general headline patterns, and widely used predictive technical indicators. We also calculate exposure to TRACON Pharmaceuticals's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to TRACON Pharmaceuticals's related companies.

Use Technical Analysis to project TRACON expected Price

TRACON Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of TRACON Pharmaceuticals technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of TRACON Pharmaceuticals trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...

How TRACON utilizes its cash?

To perform a cash flow analysis of TRACON Pharmaceuticals, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash TRACON Pharmaceuticals is receiving and how much cash it distributes out in a given period. The TRACON Pharmaceuticals cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

Purchase by Charles Theuer of 2000 shares of TRACON Pharmaceuticals

Legal trades by TRACON Pharmaceuticals insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
TRACON insider trading alert for perchase of common stock by Charles Theuer, President and CEO, on 23rd of October 2020. This event was filed by Tracon Pharmaceuticals In with SEC on 2020-10-23. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

A Deeper look at TRACON

Net Loss for the year was (17.61 M) with loss before overhead, payroll, taxes, and interest of (14.53 M).

Our perspective of the latest TRACON Pharmaceuticals rise

Value At Risk just dropped to -6.59, may entail upcoming price decrease. TRACON Pharmaceuticals is displaying above-average volatility over the selected time horizon. Investors should scrutinize TRACON Pharmaceuticals independently to ensure intended market timing strategies are aligned with expectations about TRACON Pharmaceuticals volatility.

Our Final Perspective on TRACON Pharmaceuticals

Whereas many other companies under the biotechnology industry are still a bit expensive, TRACON Pharmaceuticals may offer a potential longer-term growth to institutional investors. To conclude, as of the 19th of September 2020, we believe that at this point, TRACON Pharmaceuticals is unstable with low probability of distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. However, our concluding 30 days 'Buy-Sell' recommendation on the company is Strong Sell.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of TRACON Pharmaceuticals. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com